PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?

PDS Biotechnology has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimates over the past three months, which increased by 10.6%. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by improved earnings outlook.